Menu
At Shortwave Life Sciences, we’re driven by a focused and experienced leadership team with a wealth of knowledge in drug development, clinical research and strategy, particularly within the psychedelic field.
Co-Founder and CEO
Rivki is a Certified Public Accountant (Isr.) with a broad range of finance, strategy and business development expertise, helping to scale IP-driven start-ups in the field of life sciences. Rivki’s international experience in Asia and North America includes raising of over USD 30M for life sciences and biotech companies in the fields of diagnostics, microbiome and aesthetics, and leading go-public campaigns (NASDAQ: IMCC, CSE:IMCC). Rivki served as member of the board at several life-sciences companies and academic institutions, and as consultant to the Israeli government, accelerator programmes and investment funds,
Co-Founder & Executive director
Co-founder of Psych Capital Plc.He founded PSYCH in early 2019 to provide data and intelligence on the emerging psychedelics industry. He is also CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry’s best-known B2B companies and brands including Prohibition Partners, Business of Cannabis, Cannabis Europa and Atalis.
Stephen’s background is in technology, digital media and corporate finance, including roles with Sony Pictures, Unilever and Diageo.
Non-Executive Director
With experience of over 13 years at the highest levels of the plant-based pharma industry, Ron Lipsky has built a global network of trusting relationships in multiple verticals and geographies. As part of the founding team for MGC Pharma, Ron has listed on two exchanges (LSE and ASX) and has a wealth of experience in dealing with public markets and creating pipelines for novel treatments, from clinical studies through to government approvals. A passion for finding pathways to facilitate treatments for underserved indications and an understanding of the necessary mechanisms to leverage globally give him a unique insight to facilitate the vision of Shortwave Life Sciences.
Advisor
A Chartered Psychologist and Head of Research at Drug Science (the leading independent scientific body on drugs in the UK).
Leads the research for the Drug Science Medical Cannabis and Psychedelics Working Group.,including the improvement of patient access, with expertise across science and policy making, risk perception, risk management and risk communication.
Honorary Fellowships at Imperial College London and King’s College London.
Subscribe to receive the latest Shortwave Life Sciences news
Shortwave Life Sciences is a biopharmaceutical company developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. We identify, operate and create value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.
© 2024 Shortwave Life Sciences Plc.
All Rights Reserved.
